S&P Futures
3,884.25+16.75(+0.43%)Dow Futures
31,529.00+171.00(+0.55%)Nasdaq Futures
13,110.75+55.50(+0.43%)
BioNTech SE (BNTX)
106.00 +1.02 (0.97%)
Pre-Market: 7:45AM EST
Chart Events
Performance Outlook
| Previous Close | 110.21 |
| Open | 109.86 |
| Bid | 106.35 x 900 |
| Ask | 106.53 x 800 |
| Day's Range | 104.24 - 109.86 |
| 52 Week Range | 28.00 - 131.00 |
| Volume | 1,093,391 |
| Avg. Volume | 2,908,144 |
| Market Cap | 25.278B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Nov 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 119.09 |
- Investor's Business Daily
Merck Stepping In To Help JNJ With Covid Vaccine In 'Wartime Effort'
President Joe Biden confirmed late Tuesday that drug giant Merck will step in to help its rival, supply-constrained Johnson and Johnson, manufacture its much-needed coronavirus vaccine.
- MarketWatch
U.S. COVID vaccine supply to be boosted by Merck helping make J&J vaccine
The U.S. COVID-19 vaccine program is expected to get a welcome jolt on Tuesday in the news that one of the biggest vaccine makers in the world will help make Johnson & Johnson's one-dose jab, potentially doubling the supply from what J&J could achieve on its own.
- Reuters
UPDATE 1-France uses only quarter of Astrazeneca vaccine doses-ministry
France has used only a quarter of its AstraZeneca COVID-19 vaccine doses, a health ministry official indicated on Tuesday, saying its utilisation rate stood at 24% as of Feb. 28, well below a target set at 80-85%. This compares with 82% for vaccines made by Pfizer/BioNTech and 37% for those made by Moderna. "It is true that we are facing issues with AstraZeneca vaccines," the official said without elaborating.
